Opinion

Video

Advancements in BCG-Unresponsive NMIBC and the Impact of Trial Results and Long-Term Follow-Up

Author(s):

Max Kates, MD

Max Kates, MD, discusses how early complete response rates exceeding 50% at 3 months with newer therapies are encouraging, though long-term follow-up remains critical for evaluating durability of response and establishing real-world effectiveness compared with clinical trial outcomes.

  1. Data for newer therapies have shown that more than 50% of patients with BCG-unresponsive NMIBC experience a complete response after just 3 months of treatment. What are your thoughts on these findings?
    1. How do these clinical trial outcomes compare to what you see in your clinical practice when treating patients with newer therapies?
  2. Discuss the importance of long-term follow-up for patients receiving these newer treatments.
    1. What is your experience in terms of durability of response?
Related Videos
Related Content
© 2025 MJH Life Sciences

All rights reserved.